Form 4: Viridian Legal Chief Boosts Equity Holdings

Viridian Therapeutics' Chief Legal Officer, Jennifer Tousignant, received new equity grants and exercised existing restricted stock units, increasing her direct common stock ownership.

Summary

• Jennifer Tousignant, Chief Legal Officer of Viridian Therapeutics, Inc., reported equity transactions.
• On March 2, 2026, she was granted 119,300 stock options with an exercise price of $30.25, vesting monthly over 48 months.
• Also on March 2, 2026, she received a grant of 23,850 Restricted Stock Units (RSUs), vesting 25% annually over four years.
• On March 3, 2026, 5,169 Restricted Stock Units (from a prior grant dated March 3, 2025) vested and converted into common stock.
• Concurrently, 1,724 shares of common stock were disposed of at $29.32 per share to cover tax obligations related to the RSU vesting.
• Following these transactions, she directly holds 3,445 shares of common stock, 119,300 stock options, and 39,360 Restricted Stock Units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it reflects continued executive commitment through new equity grants and increased direct share ownership, which aligns management incentives with long-term company performance.

Positives

• New equity grants (stock options and RSUs) align management's interests with long-term shareholder value.
• The Chief Legal Officer's increased direct ownership of common stock demonstrates confidence in the company.

Negatives

• Disposal of 1,724 shares of common stock for tax withholding, though standard, represents a reduction in direct share count from the vested amount.

Future Outlook

The filing details future vesting schedules for newly granted stock options and Restricted Stock Units, indicating a long-term incentive structure for the Chief Legal Officer. The stock options will vest monthly over 48 months from March 2, 2026, and the new RSUs will vest annually over four years from March 2, 2026.

Industry Context

StockSavvy.ai notes that equity grants to key executives like the Chief Legal Officer are a standard practice in the biotechnology and pharmaceutical industries. These grants are designed to incentivize long-term performance and retention, aligning executive compensation with shareholder interests. The vesting schedules are typical for such long-term incentive plans.

Comparison to Industry Standards

• The four-year vesting schedule for both stock options and Restricted Stock Units is a common industry standard for executive compensation in the biotechnology sector, comparable to practices at companies like Moderna (MRNA) or BioNTech (BNTX) for their executive incentive plans.
• The "sell to cover" transaction for tax withholding is also a standard and expected practice when RSUs vest, seen across various industries and companies, including major tech firms like Apple (AAPL) or pharmaceutical giants like Pfizer (PFE).

Stakeholder Impact

• Shareholders: The new equity grants align the Chief Legal Officer's interests with shareholders, potentially fostering long-term value creation. The increase in direct share ownership also signals confidence.
• Employees: Standard executive compensation practices, including equity grants, can set a precedent for broader employee incentive programs.

Next Steps

• Stock options granted on March 2, 2026, will vest in 48 equal monthly installments.
• Restricted Stock Units granted on March 2, 2026, will vest 25% on each yearly anniversary of the grant date over four years.
• Remaining Restricted Stock Units from the March 3, 2025, grant will continue to vest annually over their four-year period.

Key Dates

Recommendation

This Form 4 filing primarily details routine executive compensation and tax-related transactions. While the new equity grants and increased direct ownership are positive for aligning management incentives, they do not provide new fundamental information about the company's operational performance or strategic direction that would warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and look for more substantive operational or financial updates.

Keywords

Viridian Therapeutics, VRDN, Jennifer Tousignant, Chief Legal Officer, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Grant, Share Ownership, Biotechnology, Pharmaceuticals